Allergenic characteristics of a modified peanut allergen

Attempts to treat peanut allergy using traditional methods of allergen desensitization are accompanied by a high risk of anaphylaxis. The aim of this study was to determine if modifications to the IgE‐binding epitopes of a major peanut allergen would result in a safer immunotherapeutic agent for the...

Full description

Saved in:
Bibliographic Details
Published inMolecular nutrition & food research Vol. 49; no. 10; pp. 963 - 971
Main Authors King, Nina, Helm, Ricki, Stanley, J. Steven, Vieths, Stefan, Lüttkopf, Dirk, Hatahet, Lina, Sampson, Hugh, Pons, Laurent, Burks, Wesley, Bannon, Gary A.
Format Journal Article
LanguageEnglish
Published Weinheim WILEY-VCH Verlag 01.10.2005
WILEY‐VCH Verlag
Wiley-VCH-Verl
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Attempts to treat peanut allergy using traditional methods of allergen desensitization are accompanied by a high risk of anaphylaxis. The aim of this study was to determine if modifications to the IgE‐binding epitopes of a major peanut allergen would result in a safer immunotherapeutic agent for the treatment of peanut‐allergic patients. IgE‐binding epitopes on the Ara h 2 allergen were modified, and modified Ara h 2 (mAra h 2) protein was produced. Wild‐type (wAra h 2) and mAra h 2 proteins were analyzed for their ability to interact with T‐cells, their ability to bind IgE, and their ability to release mediators from a passively sensitized RBL‐2H3 cell line. Multiple T‐cell epitopes were identified on the major peanut allergen, Ara h 2. Ara h 2 amino acid regions 11–35, 86–125, and 121–155 contained the majority of peptides that interact with T‐cells from most patients. The wAra h 2 and mAra h 2 proteins stimulated proliferation of T‐cells from peanut‐allergic patients to similar levels. In contrast, the mAra h 2 protein exhibited greatly reduced IgE‐binding capacity compared to the wild‐type allergen. In addition, the modified allergen released significantly lower amounts of β‐hexosaminidase, a marker for IgE‐mediated RBL‐2H3 degranulation, compared to the wild‐type allergen.
Bibliography:ark:/67375/WNG-W7B6LF6W-9
ArticleID:MNFR200500073
istex:E1330FFA0B6A503C1BE8BF7628E76866842AD662
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1613-4125
1613-4133
1521-3803
DOI:10.1002/mnfr.200500073